Wenjie Cheng, Ph.D., has served as Crescent’s senior vice president of technical operations since February 2025, leading CMC strategy and overseeing manufacturing operations across the company’s therapeutic portfolio. Dr. Cheng brings more than 20 years of experience in the biopharmaceutical industry, with deep expertise in process development and manufacturing for antibody and antibody drug conjugate (ADC) therapeutics. She previously served as vice president, head of US development and manufacturing center at WuXi Biologics, where she was responsible for ensuring high-quality, scalable and regulatory-compliant bioprocesses for US-based clients and facilities. Before joining WuXi Biologics, Dr. Cheng held various leadership roles at ImmunoGen, a biotechnology company specializing in ADC therapeutics (acquired by AbbVie). She began her career as a scientist at Biogen. Dr. Cheng earned her Ph.D. and MS in biophysics from New York University and her BSc in applied chemistry at Shandong University.